In vitro effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes. by Di Lorenzo, Gabriele et al.
In vitro effects of fluticasone
propionate on IL-13 production by
mitogen-stimulated lymphocytes
Gabriele Di Lorenzo1,CA, Maria Luisa Pacor2,
Maria Esposito Pellitteri1, Sebastiano Gangemi3,
Patrizia Di Blasi4, Giuseppina Candore5,
Alfredo Colombo5, Domenico Lio5 and
Calogero Caruso5
1Dipartimento di Medicina, Clinica e delle Patologie
emergenti, and 
5Dipartimento di Biopatologia e
Metologie Biomediche, Universit` a degli Studi di
Palermo, Via del Vespro 141, 90127 Palermo, Italy;
2Dipartamento di Medicina Clinica e Sperimentale,
Universit` a degli Studi di Verona, Verona, Italy;
3Dipartimento di Anatomia Umana, Universit` a degli
Studi di Messina, Messina, Italy; 
4Direzione Medica
Glaxo Smith and Kline, Verona, Italy
CACorresponding author:
Fax: +39 0916552 952
E-mail dilo601@unipa.it
BACKGROUND: Corticosteroid administration produces
multiple  immunomodulatory  effects,  including
down-regulation of  cytokine  production  by  CD4  T
lymphocytes.  Fluticasone  propionate  (FP)  (Glaxo
Smith&Kline,  Greenford,  UK),  a  highly  lipophilic
topical corticosteroid, has been shown to be safe and
effective  in  the  treatment  of  asthma  and  of  both
seasonal and perennial rhinitis.
Aims:  To  gain  insight  into  the  mechanisms  of  FP
therapeutic effects, we evaluated interleukin (IL)-13 (a
type 2 cytokine that seemingly plays a pivotal role in
allergic mechanisms) production by mitogen-stimu-
lated peripheral blood mononuclear cells  (MNC) in
vitro, treated or not with FP.
Methods:  MNC  from  10  healthy  subjects  and  10
asthmatic atopic patients with Parietaria allergy were
stimulated  v/v  with  phytohaemagglutinin  (PHA)
(50 g /ml)  or  with  complete  medium  alone  as  a
control. Culture supernatants, in vitro treated or not
with 10–7 or 10–8M FP, were collected after 48 or 72h
incubation. IL-13 production was assessed by enzyme-
linked  immunosorbent  assay.  In  random  selected
samples,  after  4  or  24h  of  cell  cultures,  RNA  was
extracted  and  IL-4  and  IL-5  reverse  transcriptase-
polymerase  chain  reaction  (RT-PCR)  products
analyzed.
Results: At 48h, there were no differences in IL-13
concentration  in  PHA-stimulated  cultures  between
healthy subjects and asthmatic patients (93.6 ± 18.9
versus  111.0  ±  25.1pg/ml).  At  72h,  similar  results
were  obtained  (63.9  ±  3.0  versus  73.3  ±  2.5pg/ml,
respectively). At this time, however, IL-13 concentra-
tions were significantly decreased versus 48h both in
asthmatics (p < 0.001)  and in controls  (p <  0.001).
Treatment with 10–7M FP significantly reduced IL-13
production in healthy subjects and asthmatic patients
both at 48h (93.6 ± 18.9 versus 50.50 ± 10.6pg/ml, p <
0.001, and 111.0 ± 25.1 versus 59.3 ± 13.6pg/ml, p <
0.001, respectively) and at 72h (63.9 ± 9.6 versus 35.5
± 4.4pg/ml, p < 0.001, and 73.3 ± 8.0 versus 40.7 ±
4.5pg/ml, p <  0.001,  respectively).  Similar  results
were obtained with 10–8M FP at 48 and 72h. Accord-
ingly, evaluation of RT-PCR products  from selected
cell samples showed a FP dosage-dependent inhibi-
tion  of  IL-4  and  IL-5  mRNA  production  both  for
healthy subjects and asthmatic patients.
Conclusions: FP in vitro impairs IL-13 production by
PHA-stimulated  MNC  from  asthmatic  and  control
subjects. This strengthens previous suggestions that
IL-13  inhibition  by  steroids  may,  at  least  in  part,
account for their therapeutic effects.
Key words: Bronchial asthma, Fluticasone propionate, IL-
13, Mitogens, Type 2 cytokines
Introduction
Corticosteroids are potent  anti-inflammatory  agents
widely used in the management of asthma and other
allergic  diseases.  Corticosteroid administration  pro-
duces multiple immunomodulatory effects, including
down-regulation  of  cytokine  production  by  CD4 T
lymphocytes.1 Cytokines produced by  lymphocytes
are classified in two types depending on their pattern
of  immune  response  regulation.  Type  1  cytokines
include  interleukin  (IL)-2,  interferon-g and  tumor
necrosis factor-b, which mediate immune responses
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type hypersensitivity.2Type 2 cytokines include IL-4,
IL-5, IL-10, and IL-13, which mediate immune respon-
ses against extracellular pathogens and regulate aller-
gic  inflammation  by  promoting  immunoglobulin  E
(IgE)  class-switching  and  eosinophil  activation.2
Although IL-4 has been considered the cytokine most
critical for allergic responses and for immunity against
parasites, recent observations indicate that IL-13,  a
related  cytokine,  has  equal  or  even  greater  impor-
tance than IL-4 in allergic inflammatory responses and
host protection against parasites.3IL-4 and IL-13 share
several  functional  properties;  however,  IL-13  can
independently induce class switching and IgE secre-
tion from human B cells. In addition, IL-13 enhances
expression of CD23 and of the major histocompatibil-
ity  complex  class  II  antigens,  and  it  may  act  as  a
monocyte  chemoattractant.4–6 Therefore,  reduction
of IL-13 production might be a key component of anti-
inflammatory drug design.
Fluticasone  propionate  (FP),  a  highly  lipophilic
topical corticosteroid (Glaxo Smith&Kline, UK), has
been shown to be safe and effective in the treatment
of asthma and of both seasonal and perennial rhinitis.
When  taken  by  the  inhaled  route,  FP  exerts  a
significant beneficial effect on asthma. Moreover, FP
had  a  higher  therapeutic  score  than  other  inhaled
corticosteroids.  Several  studies  have  demonstrated
that FP has increased intrinsic glucocorticoid potency
and  high  topical  anti-inflammatory  activity.  Clinical
studies  showed  that  FP  had  no  significant  adverse
effects, including effects on plasma cortisol concen-
trations.7–9To date, no studies have been performed
on the in vitro effect of FP on the production of IL-13.
Thus, to investigate the mechanisms underlying the
therapeutic effects of FP, we evaluated IL-13 produc-
tion by  peripheral blood mononuclear  cells  (MNC)
stimulated  with  phytohemagglutinin  (PHA),  treated
or not with FP.
Materials and methods
Subjects
After  informed  consent  was  obtained,  peripheral
blood  was  withdrawn  from  healthy  subjects  (labo-
ratory  staff,  n =  10)  and  from  asthmatic  atopic
patients  (n =  10)  with  Parietaria  allergy.  Allergic
asthmatic patients had a history of more than 2 years
of symptoms consistent with asthma, and a methacho-
line  PC20 of  16mg/ml  or  less.10 Serum-specific  IgE
and skin prick tests were performed and evaluated
exactly as previously described elsewhere.10,11
Fluticasone propionate
Pure  FP  was  obtained  from  Glaxo  Smith&Kline
(Verona,  Italy)  and  dissolved  in  anhydrous  ethanol
(95%) at a concentration of 10–3M. It was then diluted
at  concentration  of  10–7 or  10–8M  in  complete
medium  (i.e.  RPMI-1640)  (GIBCO,  Gran Island, NY,
USA) supplemented with 10% heat-inactivated pool of
AB  sera  (AB  Pool;  Flow  Laboratories,  Irvine,  UK),
glutamine  (Flow),  gentamycin,  streptomycin  and
Hepes buffer (Boeringer Mannehim, Mannheim, Ger-
many). Control medium was prepared using the same
dilution of ethanol.11
Cell cultures and IL-13 assay
MNC from  healthy volunteers and asthmatic atopic
subjects  were  isolated  by  centrifugation  on  Ficoll
Hipaque  gradient  (Nycomed  As,  Diagnostic,  Oslo.
Norway), washed twice in complete medium, and 5
´ 106/ml  cells  were  stimulated  v/v  with  PHA
(50g/ml) (Sigma, Milan, Italy) or, as a control, with
complete  medium  alone.  These  PHA  doses  were
used because, in our hands, they have been demon-
strated to be optimal ones.12 Culture  supernatants,
with and without 10–7 or 10–8M FP, were collected
after an incubation of 48 or 72h and stored at –70°C
until  assayed.  IL-13  production  was  assessed  by
enzyme-linked  immunosorbent  assay  with  Quanti-
kine™ immunoassay kits (R&D System Inc, Minnea-
polis,  MN,  USA)  according  to  the  manufacturer’s
instructions. All  standards and samples were  tested
in  duplicate.  IL-13  results  were  calculated as  pico-
grams  per  millilitre.  The  detection  limit  in  our
laboratory was 32pg/ml.
RNA extraction and mRNA synthesis
evaluation
In  random selected samples, after 4  or 24h of cell
cultures,  RNA  was  extracted  using  the  method
described  by  Gough.13 IL-4  and  IL-5  reverse  tran-
scriptase-polymerase  chain  reaction  (RT-PCR)  prod-
ucts  (294pb  for  IL-5  and  344pb  for  IL-4)  were
detected  by  electrophoresis  on  2%  agarose  and
analysed  by  1D  Image  Analysis  Software  (Eastman
Kodak Co., Rochester, NY, USA).
Statistical analysis
The results are expressed as mean ± standard error of
the  mean  (SEM)  for  convenience  of  presentation.
Because  the  distribution  of  data  was  not  normally
distributed, non-parametric tests were used for Statis-
tical Analysis. The Wilcoxon matched pairs test was
used to compare intragroup differences of IL-13, and
the  Mann–Whitney  U-test  was  used  to  compare
intergroup  differences  of  IL-13.  All  analyses  were
performed using StatsDirect (Tidestone Technologies
Inc, Cambridge, UK) on a PC. p£  0.05 was considered
significant.
G. Di Lorenzo et al.
188 Mediators of Inflammation · Vol 11 · 2002Results
IL-13 production by stimulated cultures treated or not
treated with FP from asthmatic and healthy individ-
uals  was  evaluated  both  at  48  and  at  72h  (Fig.
1a,b).
IL-13  was  detected in  both  healthy  subjects  and
asthmatic patients at 48 and 72h. At 48h, the values
of PHA-stimulated cultures did not differ between the
two  groups  (93.6  ±  6.0  versus  111.0  ±  7.9pg/ml,
respectively).  Similar  results  were  obtained  at  72h
(63.9 ± 3.0 versus 73.3 ± 2.5pg/ml, respectively). The
lack  of  difference  in  IL-13  production  between
healthy subjects and asthmatic patients was probably
due  to  the  small  samples  of  subjects  under  study.
However, 72h IL-13 concentrations were significantly
decreased when compared with 48h concentrations
in  healthy  subjects  and  in  asthmatic  patients  (p <
0.001 for both).
Treatment of cultures with 10–7M FP significantly
reduced IL-13 production in healthy subjects and in
asthmatic  patients  both  at  48h  (93.6  ±  6.0  versus
50.50 ± 3.3pg/ml, p < 0.001, and 111.0 ± 7.9 versus
59.3 ± 4.3pg/ml, p < 0.001, respectively) and at 72h
(63.9 ± 3.0 versus 35.5 ± 1.6pg/ml, p < 0.001, and
73.3  ±  2.5  versus  40.7  ±  1.4pg/ml,  p <  0.001,
respectively).  Similar  results  were  obtained  with
10–8M  FP  in  healthy  subjects  and  in  asthmatic
patients both at 48h (93.6 ± 6.0 versus 59.5 ± 3.8pg/
ml, p <0.001, and 111.0 ± 7.9 versus 70.5 ± 5.1pg/ml,
p <0.001, respectively) and at 72h (63.9 ± 3.0 versus
40.1 ± 1.6pg/ml, p <0.001, and 73.3 ± 2.5 versus 45.5
± 1.5pg/ml, p < 0.001, respectively).
In preliminary experiments, cells from 4h (or 24h)
stimulated  cultures  treated  or  not  treated  with  FP
from  healthy  subjects  and  asthmatic  patients  were
collected  to  measure,  respectively,  IL-4  and  IL-5
mRNA.  Evaluation  of  RT-PCR  products  from  cells
cultured in presence of FP (10–7 and 10–8M) showed
a dosage-dependent inhibition of IL-4 and IL-5 mRNA
production both for  healthy subjects and asthmatic
patients.
Discussion
The  local  production  and  release  of  a  number  of
cytokines  regulate  allergic  upper  airway  inflamma-
tion. In particular, a large body of evidence indicates
that IL-13 may play a crucial role in the inflammatory
reaction.3–5,14 IL-13  shares many  functional  similar-
ities  with  IL-4,  including  the  capacity  to  induce
immunoglobulin isotype switching to IgE in B cells.
IL-13 also causes de novo surface expression of the
vascular  cell  adhesion  molecule  1  (VCAM-1)  on
endothelial cells of the umbilical vein and accelerates
selective eosinophil migration. Interestingly, IL-13 up-
regulates  VCAM-1  expression  in  human  mucosal
microvascular endothelial cells, to which eosinophils
adhere in bronchial and nasal mucosa. Finally, IL-13
concentrations are  strongly  correlated with  eosino-
phil numbers in bronchoalveolar lavage after allergen
challenge.4,5,14 Consequently, it is not inconceivable
that IL-13 is important in the pathogenesis of  such
eosinophil-related  inflammatory  disorders  as  nasal
allergy and bronchial asthma.
Corticosteroids have proven efficacy in the treat-
ment of allergic respiratory disorders and, regularly
administered,  they  inhibit  both  the  immediate  and
late response to allergen provocation. They exert an
effect on a number of cells involved in the allergic
inflammatory reaction, including down-regulation of
Fluticasone propionate and IL-13
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FIG. 1. (a) IL-13 levels in supernatants of PHA-stimulated 48h
cultures  from  healthy  subjects  (n =  10)  and  asthmatic
patients (n = 10). Cultures were treated with 10
–7M FP, 10
–8M
FP or control medium. Results are expressed as mean ± SEM
of  individual  values  (pg/ml).  There  were  no  significant
differences between values of the PHA-stimulated cultures
from the two groups of individuals. Treatment with 10
–7M FP
significantly reduced the IL-13 production of both groups of
subjects. The same results were obtained with 10
–8M FP. (b)
IL-13 levels in supernatants of PHA-stimulated 72h cultures
from healthy subjects (n = 10) and asthmatic patients (n = 10).
Cultures were treated with 10
–7M FP, 10
–8M FP or control
medium. Results are expressed as mean ±SEM of individual
values  (pg/ml).  There  were  no  significant  differences
between values of the PHA-stimulated cultures from the two
groups of individuals. Treatment of cultures with 10
–7M FP
significantly reduced the IL-13 production of both groups of
subjects.cytokine production, including IL-13,1,6–9,14,15 which
may  explain  their  potent  effect  in  clinical  allergy
studies. However, topical steroids control the inflam-
matory  cell  influx  that  increases  the  potential  for
leukotriene  generation  responsible  for  clinical
symptoms.1
Recently, we investigated the effects of intranasal
FP  on  subjective  symptoms  and  on  pathophysio-
logical mechanisms in rhinitis patients monosensitive
to Parietaria during the pollen season. The concentra-
tions of  eosinophils and inflammatory mediators in
nasal  lavages  and  subjective  symptoms  decreased
significantly following FP treatment. The inhibition by
FP  of  mast  cells,  eosinophils  and  neutrophils  was
clearly  demonstrated by  the  reduced  level  of  their
mediators in nasal lavage fluid (i.e. tryptase, eosino-
phil  cationic  protein,  eosinophil  protein  X,  and
neutrophil  myeloperoxidase).  Similarly,  flow  cyto-
metric  studies  have  shown  that  FP  decreases  the
influx  of  total and  activated eosinophils  in  rhinitis
patients. Thus, we demonstrated that FP could influ-
ence both the cells of the early phase and those of the
delayed phase of the allergic reaction.8 In a further
study, we demonstrated that in vitro treatment with
FP  impaired  natural  killer  and  lymphokine-induced
killer  activity  in  asthmatic  and  healthy  individuals,
suggesting  a  key  role  in  this  process  for  cytokine
impairment by the drug.11
In a previous study, the expression of IL-13 mRNA
and  immunoreactivity  in  nasal  biopsies  from  10
normal subjects and 20 subjects with allergic rhinitis
was  investigated. After  allergen  provocation,  a  sig-
nificant increase in IL-13 mRNA-positive and immu-
noreactive  cells  at  24h  only  in  subjects  given  pla-
cebo  was  observed.  Thus,  inhibition  of  the  late
phase after corticosteroid treatment was associated
with  a  marked  decrease  in  allergen-induced  IL-13
mRNA-positive and immunoreactive cells. This study
suggests that IL-13 expression is a prominent feature
of the late phase in the nose and that inhibition of
the  late  phase  by  steroid  therapy  might  be  partly
attributable  to  inhibition  of  IL-13  expression.14 In
nasal  polyp  disease,  intranasal  fluticasone  also
reduced the number of IL-4 and IL-13 mRNA+ cells,
but  the  expression  of  proinflammatory  cytokines
was relatively  unaffected by  fluticasone treatment.6
Finally, preventive treatment of intranasal FP reduced
cytokine mRNA-expressing cells before and during a
single  nasal  allergen  provocation.  Preventive  treat-
ment with FP out of season resulted in a decrease in
eosinophils  and  mRNA-positive  cells  for  type  2
cytokines. After allergen provocation, levels of most
of  the  measured  cytokines,  including  IL-13,  and  of
eosinophils  were  reduced  using  corticosteroids.
Thus, preventive treatment with FP prior to contact
with  grass  pollen  was  effective  in  reducing  the
increase of cytokine mRNA-positive cells in reaction
to grass-pollen contact.14
The present results clearly show that FP in vitro
impairs IL-13 production by PHA-stimulated lympho-
cytes  from  both  asthmatic and control subjects.  In
accord with these data, our preliminary results seems
to confirm that IL-4  and IL-5 mRNA production by
PHA-stimulated lymphocytes from both asthmatic and
control  subjects  might  be  inhibited  by  FP.  On  the
whole, previous and present results demonstrate that
type 2 cytokine inhibition by steroid may, at least in
part, account for its therapeutic effects.
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